Purpose: In the treatment of breast cancer, neoadjuvant chemotherapy (NAC) is useful to reduce breast cancer size before surgical intervention. Patients who achieve a pathologic complete response (pCR) to NAC have improved overall survival (OS). However, the relationship between prognosis and partial response is yet unclear. In this study, we evaluated prognostic factors and the tumor response ratio (TRR) method among patients who received NAC. Methods: Clinicopathologic factors were evaluated to predict OS. The TRR was calculated by dividing pathologic tumor size by clinical tumor size. TRRs were then categorized into four groups, and the survival times for the different TRR groups were compared using statistical evaluation. Results: Clinical N stage (p= 0.02), overall stage (p= 0.04), pathologic N stage (p= 0.03), hormone receptor status (p= 0.01), and lymphovascular invasion (p= 0.02) were significantly associated with OS. Pathologic overall stage and TRR did not correlate with OS. Patients with a pCR exhibited the best survival rates using the current staging system and the TRR method. Conclusion: Clinicopathologic factors can be easily applied to predict OS, and clinicians could use these parameters until an accurate, simple, and highly discriminatory methods is developed to assess breast cancer patients with a partial.
INTRODUCTION
Cancer staging systems provide information that allows both clinicians and patients to design an optimal treatment and follow-up plan.
Staging also allows for ease of communication among clinicians across multiple disciplines. Neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced breast cancer and has been increasingly implemented for treatment of patients with earlier stage operable cancer [1, 2] . Because NAC results in improvements in disease-free survival (DFS) and overall survival (OS), which are similar to those obtained with adjuvant chemotherapy [3, 4] , NAC is used not only to reduce breast cancer size before surgical intervention but also to convert locally advanced inoperable breast cancer to operable disease [5] [6] [7] .
Patients who show pathologic complete responses (pCRs) to NAC have improved OS [8, 9] . However, achieving a pCR is relatively uncommon, and there are only a few known predictive factors for OS in patients with partial responses [10] [11] [12] . Currently, breast cancer pathologic stage is evaluated using the American Joint Committee on Cancer (AJCC) tumor-node-metastasis classification system [13] . However, AJCC staging does not consider the effects of NAC, which is a common treatment modality for breast cancer. Clinical response to NAC would be a more precise way of describing the effect of NAC, and clinical response is evaluated according to the response evaluation criteria in solid tumors (RECIST) version 1.1 [14] . A pCR is defined as the complete disappearance of invasive cancer in both breast and axillary lymph nodes. Partial response is defined as a >30% reduction in the largest tumor diameter. Progressive disease (PD) is defined as an increase of at least 20% from the base line diameter or the appearance of new disease. The lack of sufficient tumor shrinkage to qualify as partial response or a sufficient increase in tumor to qualify as PD is regarded as stable disease.
Several methods that attempt to predict the prognosis of patients with partial responses to NAC have been proposed [10, 11, 15] . However, these methods have not been properly validated and are limited be-109 cause of their complex calculations and unusual parameters. Therefore, no standard classification system for reporting responses to NAC exists. A method to predict survival rates of patients with partial responses to NAC would allow individualized treatment and surveillance. Therefore, we evaluated prognostic factors in a neoadjuvant setting. We also validated the tumor response ratio (TRR) method, which is a staging method for predicting the prognosis of breast cancer with a partial response after NAC, because this method is easily applicable using only clinical and pathologic tumor sizes and it accurately predicts OS [15] .
METHODS

Patients
This study was performed retrospectively by using the records of 
Research methods
Tumor location, operation method, histologic type, clinical and pathologic stage, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, tumor grade, presence of lymphovascular invasion (LVI), and margin status were evaluated as prognostic factors for survival after NAC.
The TRR method was implemented as previously described [15] .
Tumor size prior to NAC was determined at the time of diagnosis using imaging modalities. Most patients were diagnosed using multiple imaging techniques. Magnetic resonance imaging (MRI) was the method of choice in this study; however, if MRI results were not available, ultrasonography was used as an alternative method. Only the diameter of the largest mass was used as a factor for TRR. Pathologic tumor sizes were obtained from pathologic reports after breast resection surgery. TRR was defined as (pathologic tumor size/prechemotherapy tumor size), and values were categorized into four risk groups, as in a previously published TRR study [15] . TRR 0 (pCR) signified complete 
Statistical analysis
To evaluate patient characteristics, the frequency analysis method was used. The Kaplan-Meier method and log-rank test were used to estimate survival, according to clinicopathologic factors. Using Cox hazard regression analysis, multivariate analyses were conducted to evaluate the effects of independent variables on dependent variables.
Statistical analyses were performed using PASW Statistics version 18.0 (SPSS Inc., Chicago, USA). Reported p-values are two-sided, and statistical significance was set at p < 0.05. Table 1 shows the patient clinicopathologic characteristics. The mean age of our study group was 49 years at the time of diagnosis. Of 218 patients, 179 (82.1%) were assessed for pretreatment cancer size using MRI. Thirty-nine patients (17.9%) did not undergo MRI; therefore, ultrasonography was used for assessing tumor size. Most patients were diagnosed with invasive ductal carcinoma (n =191, 87.6%), clinical T2 lesions (n =139, 63.8%), and clinical N1 tumors (n = 96, 44.0%).
RESULTS
Patients
For pathologic stage, ypT1 (n = 86, 39.5%) and ypN0 (n = 97, 44.5%) were the most common, and for final pathologic stage, stage II (n =78, 35.8%) was the most common. The dominant disease subtypes were
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hormone receptor-negative (n =118, 54.1%) and HER2-negative (n =144, 66.1%). Most patients were negative for LVI (n =153, 70.2%).
Tumor response ratio
There were 41 patients (18.8%) in the pCR category. Sixty-six patients (30.3%) were in the SPR group, 87 patients (39.9%) were in the WPR group, and 24 patients (11.0%) were in the TG group. Table 2 shows the TRR according to receptor status and mortality. More than 20% of patients in the hormone receptor-negative group achieved a pCR, whereas, about 10% of the hormone receptor-positive group showed a pCR. Although the pCR rate was higher in the hormone receptor-negative group, mortality was more frequently observed in this group.
Clinical outcomes
During a mean follow-up of 44 months, 61 patients (28.0%) experienced locoregional and/or distant disease recurrences, and 23 patients (10.6%) died. Table 1 shows the number of patients who died of any cause, and Table 3 Significant factors from univariate analyses were assessed by multivariate analyses using the Cox regression method to evaluate prognostic significance (Table 3) Although pathologic overall stage and TRR tended to predict good responses and better OS, they were not statistically significant. However, patients with pathologic complete remission had the best survival rate when using the current pathologic staging and TRR methods.
DISCUSSION
The wide use of NAC has made breast cancer staging more complex. Unfortunately, the current staging system cannot incorporate the response to NAC. It is unclear whether initial clinical stage or post-NAC pathologic stage is more significant for prognosis. Therefore, efforts have been made to examine the predictive value of clinicopathologic factors and tumor responses to NAC [8, 10, 11, 16] . Pathologic complete remission is a well-known predictive factor for improved OS [8, 16] . Additionally, the degree of tumor response and the extent of residual disease after NAC are associated with survival. However, there is no standard classification system for reporting responses to NAC.
Therefore, we evaluated the prognostic value and utility of TRR methods to predict survival after NAC for breast cancer.
In this study, multivariate analysis showed that clinical N stage This study is limited by several factors. First, the data are from a small cohort of patients who were heterogeneously treated, as well as a high-risk population treated with aggressive multimodal therapy.
Furthermore, different imaging techniques, including MRI and ultrasonography, were used to assess pretreatment tumor size. We chose MRI as the main method in this study because it is highly sensitive for detecting invasive breast cancer and shows excellent correlation between the gross histology size and the size determined using MRI [20, 21] . Thirty-nine patients were assessed using ultrasonography, which may not be comparable. For this reason, our results may not be generalizable until multi-institution, large cohort studies with longer follow-up durations are performed.
In this study, we could not validate the efficacy of TRR for patients with a partial response. However, we found useful clinicopathologic prognostic factors for all patients and patients with a partial response after NAC. As these factors are easily applicable, clinicians can use them to predict the prognosis after NAC for all patients, including those with a partial response.
